Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Sanofi, multiple myeloma
Sanofi wins US approval for drug combination to treat multiple myeloma
Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed multiple myeloma, where it has previously been used only after standard treatments have failed,
Sanofi breaks into first-line multiple myeloma with FDA approval for Sarclisa
Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated multiple myeloma. That changed Friday. | Since an initial FDA go-ahead in 2020,
Sanofi’s Multiple Sclerosis Drug Slows Disease’s Progression
Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, providing hope for patients for whom there’s currently no treatment.
Sanofi wins US approval for multiple myeloma drug in newly diagnosed patients
The U.S. Food and Drug Administration said on Friday it has approved the use of a drug combination along with Sanofi's Sarclisa infusion as a treatment for certain types of newly diagnosed multiple myeloma patients.
Cure Today
1d
FDA Approves Sarclisa In Newly Diagnosed Transplant-Ineligible Multiple Myeloma
The Food and Drug Administration has approved Sarclisa as a first-line treatment for patients with
multiple myeloma
who are ...
Targeted Oncology
1d
Efficacy of Cilta-Cel Is Maintained in Early Relapsed Multiple Myeloma
During a Case-Based Roundtable® event, Samer A. Al'Hadidi, MD, MS, discussed the CARTITUDE-4 trial of cilta-cel in patients ...
The American Journal of Managed Care
1d
FDA Approves Isatuximab With VRd as First-Line Option for Transplant-Ineligible Multiple Myeloma
Isatuximab (Sarclisa) with bortezomib, lenalidomide, and dexamethasone (VRd) is now an approved option for adults who cannot ...
11d
on MSN
Multiple myeloma gets new attention after Patti Scialfa, Bruce Springsteen's wife and bandmate, reveals diagnosis
The news that Patti Scialfa, Bruce Springsteen’s wife and bandmate, has multiple myeloma is bringing attention to the rare ...
7d
on MSN
Multiple myeloma, rare blood cancer: Bruce Springsteen's wife's diagnosis spotlights the illness
Patti Scialfa, Bruce Springsteen’s wife, recently shared that she was diagnosed in 2018 with a type of blood cancer known as ...
The American Journal of Managed Care
1d
Varied Types, Levels of Support Needed for Patients With Multiple Myeloma
Information on the disease and treatments, assistance with insurance, and transportation are among the types of support ...
Today
21h
Patti Scialfa, wife and bandmate of Bruce Springsteen, performs after revealing cancer diagnosis
15, at Sea.Hear.Now Festival at Asbury Park in New Jersey. Scialfa publicly shared her 2018 diagnosis with blood cancer
multiple myeloma
in “Road Diary: Bruce Springsteen and the E Street Band.” ...
4d
on MSN
Inherited changes in BRCA genes linked to increased risk of multiple myeloma
A significant number of multiple myeloma patients may have an inherited but previously unrecognized risk of developing the ...
8d
Patti Scialfa's Cancer Diagnosis: What To Know About Multiple Myeloma
Patti Scialfa, Bruce Springsteen’s Wife and E Street Bandmate, has been diagnosed with multiple myeloma. Find out more on ...
Targeted Oncology
1d
FDA Approves Isatuximab Plus VRd in Transplant-Ineligible Multiple Myeloma
The approval is supported by data from the phase 3 IMROZ study which demonstrated superior progression-free survival with ...
vator
2d
The International Myeloma Foundation unveils AI-based chatbot
In order to help provide answers to these questions, and to provide support to patients and their caregivers, The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Sanofi
Food and Drug Administration
Sarclisa
GSK
GlaxoSmithKline
Feedback